Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Executive Summary
The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone-resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication
You may also be interested in...
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting
Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain
Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.